Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHAD ROGER HUBERTY

Allopathic & Osteopathic Physicians Family Medicine

NPI
1407852304
CMS profile
290991
Location
MYRTLE BEACH, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,007.26

127 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,007.26 127

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHAD ROGER HUBERTY

NPI 1407852304 · CMS profile ID 290991

Allopathic & Osteopathic Physicians / Family Medicine

MYRTLE BEACH, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407852304?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHAD ROGER HUBERTY, NPI 1407852304, CMS profile ID 290991. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407852304?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). CHAD ROGER HUBERTY, NPI 1407852304, CMS profile ID 290991. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407852304?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
CHAD ROGER HUBERTY, NPI 1407852304, CMS profile ID 290991, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1407852304?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

127 matching records · $2,007.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 127 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–127 of 127.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $13.2203/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105514753 CMS
ABBVIE INC. $10.9003/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103949814 CMS
Amgen Inc. $19.2103/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602800 CMS
UCB, Inc. $21.3102/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143509299 CMS
Novartis Pharmaceuticals Corporation $1.8302/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086891585 CMS
Novartis Pharmaceuticals Corporation $25.6202/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086891587 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.5402/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117998083 CMS
Radius Health, Inc. $13.7402/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089941489 CMS
Novartis Pharmaceuticals Corporation $12.6302/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086891561 CMS
ABBVIE INC. $20.0502/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103949812 CMS
Otsuka America Pharmaceutical, Inc. $23.2802/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118910723 CMS
Alexion Pharmaceuticals, Inc. $14.4502/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093917714 CMS
UCB, Inc. $17.5502/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143509293 CMS
GlaxoSmithKline, LLC. $13.3701/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116427448 CMS
ABBVIE INC. $14.1001/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103949810 CMS
UCB, Inc. $18.2101/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143509287 CMS
Amgen Inc. $17.6401/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602778 CMS
Daiichi Sankyo Inc. $17.7101/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089435290 CMS
SANOFI-AVENTIS U.S. LLC $23.8401/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139722792 CMS
Aurinia Pharma U.S., Inc. $23.7001/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150682909 CMS
Novo Nordisk Inc $23.9401/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097586659 CMS
Novo Nordisk Inc $10.3001/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097797632 CMS
Amgen Inc. $17.6601/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111602790 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.3301/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086173860 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.1901/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117998087 CMS
ABBVIE INC. $7.3601/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103949808 CMS
Novartis Pharmaceuticals Corporation $11.8801/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086891557 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,902.34 147
PY2020 $1,027.23 73
PY2021 $1,089.47 70
PY2022 $1,278.30 83
PY2023 $1,589.41 96
PY2024 $2,007.26 127
PY2025 $1,144.87 58

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $52,216.82 36
PY2024 Principal investigator $47,301.71 7
PY2023 Principal investigator $360,520.40 102
PY2022 Principal investigator $105,344.55 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $18,350.00 12/31/2025 Non-covered Recipient Entity
TMA Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228726032
Principal investigator 1 PFIZER INC. $19,452.82 12/27/2025 Non-covered Recipient Entity
TMA Headlands LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228726086
Principal investigator 1 PFIZER INC. $1,170.00 12/11/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228728665
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725384
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725402
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725466
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725568
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725638
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725908
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228726000
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228726002
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228730930
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228732284
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228732458
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228732463
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228732715
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228732962
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228732967
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228732973
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228733589
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228733771
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735188
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735296
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725552
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725572
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725668
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725838
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725910
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228726004
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228733776
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228733781
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228733997
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228734845
Principal investigator 1 PFIZER INC. $265.20 11/18/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228724300
Principal investigator 1 PFIZER INC. $36.16 11/18/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228724778
Principal investigator 1 PFIZER INC. $144.64 11/18/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228728473